Global Hyperhidrosis Treatment Market

Hyperhidrosis Treatment Comprehensive Study by Type (Antiperspirants, Iontophoresis, Botulinum toxin injections, Prescription cloth wipes, Prescription medicine, Surgery), Application (Hospitals, Dermatology Clinics, Other), Disease Type (Primary Focal Hyperhidrosis, Secondary Generalized Hyperhidrosis), Diagnosis (Physical Examination, Sweat Test, Others) Players and Region - Global Market Outlook to 2030

Hyperhidrosis Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Hyperhidrosis Treatment
Hyperhidrosis is a condition characterized by excessive sweating that is not necessarily related to heat or exercise. It is estimated that roughly 3% of the world’s population i.e. around 200 million people have this medical condition. It can affect just one specific area or the whole body. It is normally most active in the hands, feet, armpits, and the groin because of their relatively high concentration of sweat glands. It may be present from birth or might develop later in life. Hyperhidrosis treatment depends on the type of hyperhidrosis and where the excessive sweating occurs on the body.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Hyperhidrosis Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Allergan, Inc. (United States), GlaxoSmithKline Plc (United Kingdom), Revance Therapeutics Inc. (United States), Ulthera, Inc. (United States), TheraVida, Inc. (United States), Dermira, Inc. (United States) and Sientra Inc. (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Hyperhidrosis Treatment market by Type (Antiperspirants, Iontophoresis, Botulinum toxin injections, Prescription cloth wipes, Prescription medicine and Surgery), Application (Hospitals, Dermatology Clinics and Other) and Region.



On the basis of geography, the market of Hyperhidrosis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Disease Type, the sub-segment i.e. Primary Focal Hyperhidrosis will boost the Hyperhidrosis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Physical Examination will boost the Hyperhidrosis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Focus on Preventive Healthcare

Market Growth Drivers:
Increase in the Prevalence of Hyperhidrosis, Development of New Diagnostic Centres and Hospitals and Increase in the Research Activities

Challenges:
Stringent Government Rules and Regulations

Restraints:
Less Awareness among People

Opportunities:
Rising Regulatory Approval for Hyperhidrosis Medicines and Growing Healthcare Industry Worldwide

Market Leaders and their expansionary development strategies
In January 2019, GlaxoSmithKline plc has announced that it has successfully completed the acquisition of TESARO, Inc. an oncology-focused company based in Waltham, Massachusetts.
In April 2023, Candesant Biomedical a private medical device company focused on the development and commercialization of non-invasive treatments for hyperhidrosis or excessive sweating not always related to heat or exercise, today announced the U.S. Food and Drug Administration (FDA) granted a de novo request for Brella™, the first and only 3-Minute SweatControl Patch™ for the reduction of excessive underarm sweating in adults with primary axillary hyperhidrosis. Brella uses Candesant's novel, patented TAT (targeted alkali thermolysis) technology.


Key Target Audience
Hyperhidrosis Treatment Providers, Research Professionals, Emerging Companies, Distributors, Government Body and Associations and End-users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Antiperspirants
  • Iontophoresis
  • Botulinum toxin injections
  • Prescription cloth wipes
  • Prescription medicine
  • Surgery
By Application
  • Hospitals
  • Dermatology Clinics
  • Other
By Disease Type
  • Primary Focal Hyperhidrosis
  • Secondary Generalized Hyperhidrosis

By Diagnosis
  • Physical Examination
  • Sweat Test
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Prevalence of Hyperhidrosis
      • 3.2.2. Development of New Diagnostic Centres and Hospitals
      • 3.2.3. Increase in the Research Activities
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Growing Focus on Preventive Healthcare
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hyperhidrosis Treatment, by Type, Application, Disease Type, Diagnosis and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hyperhidrosis Treatment (Value)
      • 5.2.1. Global Hyperhidrosis Treatment by: Type (Value)
        • 5.2.1.1. Antiperspirants
        • 5.2.1.2. Iontophoresis
        • 5.2.1.3. Botulinum toxin injections
        • 5.2.1.4. Prescription cloth wipes
        • 5.2.1.5. Prescription medicine
        • 5.2.1.6. Surgery
      • 5.2.2. Global Hyperhidrosis Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Dermatology Clinics
        • 5.2.2.3. Other
      • 5.2.3. Global Hyperhidrosis Treatment by: Disease Type (Value)
        • 5.2.3.1. Primary Focal Hyperhidrosis
        • 5.2.3.2. Secondary Generalized Hyperhidrosis
      • 5.2.4. Global Hyperhidrosis Treatment by: Diagnosis (Value)
        • 5.2.4.1. Physical Examination
        • 5.2.4.2. Sweat Test
        • 5.2.4.3. Others
      • 5.2.5. Global Hyperhidrosis Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Hyperhidrosis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Revance Therapeutics Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Ulthera, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. TheraVida, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Dermira, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sientra Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
  • 7. Global Hyperhidrosis Treatment Sale, by Type, Application, Disease Type, Diagnosis and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hyperhidrosis Treatment (Value)
      • 7.2.1. Global Hyperhidrosis Treatment by: Type (Value)
        • 7.2.1.1. Antiperspirants
        • 7.2.1.2. Iontophoresis
        • 7.2.1.3. Botulinum toxin injections
        • 7.2.1.4. Prescription cloth wipes
        • 7.2.1.5. Prescription medicine
        • 7.2.1.6. Surgery
      • 7.2.2. Global Hyperhidrosis Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Dermatology Clinics
        • 7.2.2.3. Other
      • 7.2.3. Global Hyperhidrosis Treatment by: Disease Type (Value)
        • 7.2.3.1. Primary Focal Hyperhidrosis
        • 7.2.3.2. Secondary Generalized Hyperhidrosis
      • 7.2.4. Global Hyperhidrosis Treatment by: Diagnosis (Value)
        • 7.2.4.1. Physical Examination
        • 7.2.4.2. Sweat Test
        • 7.2.4.3. Others
      • 7.2.5. Global Hyperhidrosis Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hyperhidrosis Treatment: by Type(USD Million)
  • Table 2. Hyperhidrosis Treatment Antiperspirants , by Region USD Million (2018-2023)
  • Table 3. Hyperhidrosis Treatment Iontophoresis , by Region USD Million (2018-2023)
  • Table 4. Hyperhidrosis Treatment Botulinum toxin injections , by Region USD Million (2018-2023)
  • Table 5. Hyperhidrosis Treatment Prescription cloth wipes , by Region USD Million (2018-2023)
  • Table 6. Hyperhidrosis Treatment Prescription medicine , by Region USD Million (2018-2023)
  • Table 7. Hyperhidrosis Treatment Surgery , by Region USD Million (2018-2023)
  • Table 8. Hyperhidrosis Treatment: by Application(USD Million)
  • Table 9. Hyperhidrosis Treatment Hospitals , by Region USD Million (2018-2023)
  • Table 10. Hyperhidrosis Treatment Dermatology Clinics , by Region USD Million (2018-2023)
  • Table 11. Hyperhidrosis Treatment Other , by Region USD Million (2018-2023)
  • Table 12. Hyperhidrosis Treatment: by Disease Type(USD Million)
  • Table 13. Hyperhidrosis Treatment Primary Focal Hyperhidrosis , by Region USD Million (2018-2023)
  • Table 14. Hyperhidrosis Treatment Secondary Generalized Hyperhidrosis , by Region USD Million (2018-2023)
  • Table 15. Hyperhidrosis Treatment: by Diagnosis(USD Million)
  • Table 16. Hyperhidrosis Treatment Physical Examination , by Region USD Million (2018-2023)
  • Table 17. Hyperhidrosis Treatment Sweat Test , by Region USD Million (2018-2023)
  • Table 18. Hyperhidrosis Treatment Others , by Region USD Million (2018-2023)
  • Table 19. South America Hyperhidrosis Treatment, by Country USD Million (2018-2023)
  • Table 20. South America Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 21. South America Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 22. South America Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 23. South America Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 24. Brazil Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 25. Brazil Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 26. Brazil Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 27. Brazil Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 28. Argentina Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 29. Argentina Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 30. Argentina Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 31. Argentina Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 32. Rest of South America Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 33. Rest of South America Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 34. Rest of South America Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 35. Rest of South America Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 36. Asia Pacific Hyperhidrosis Treatment, by Country USD Million (2018-2023)
  • Table 37. Asia Pacific Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 38. Asia Pacific Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 39. Asia Pacific Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 40. Asia Pacific Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 41. China Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 42. China Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 43. China Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 44. China Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 45. Japan Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 46. Japan Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 47. Japan Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 48. Japan Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 49. India Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 50. India Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 51. India Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 52. India Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 53. South Korea Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 54. South Korea Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 55. South Korea Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 56. South Korea Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 57. Taiwan Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 58. Taiwan Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 59. Taiwan Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 60. Taiwan Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 61. Australia Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 62. Australia Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 63. Australia Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 64. Australia Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 69. Europe Hyperhidrosis Treatment, by Country USD Million (2018-2023)
  • Table 70. Europe Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 71. Europe Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 72. Europe Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 73. Europe Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 74. Germany Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 75. Germany Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 76. Germany Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 77. Germany Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 78. France Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 79. France Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 80. France Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 81. France Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 82. Italy Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 83. Italy Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 84. Italy Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 85. Italy Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 86. United Kingdom Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 87. United Kingdom Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 88. United Kingdom Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 89. United Kingdom Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 90. Netherlands Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 91. Netherlands Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 92. Netherlands Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 93. Netherlands Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 94. Rest of Europe Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 95. Rest of Europe Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 96. Rest of Europe Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 97. Rest of Europe Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 98. MEA Hyperhidrosis Treatment, by Country USD Million (2018-2023)
  • Table 99. MEA Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 100. MEA Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 101. MEA Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 102. MEA Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 103. Middle East Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 104. Middle East Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 105. Middle East Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 106. Middle East Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 107. Africa Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 108. Africa Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 109. Africa Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 110. Africa Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 111. North America Hyperhidrosis Treatment, by Country USD Million (2018-2023)
  • Table 112. North America Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 113. North America Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 114. North America Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 115. North America Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 116. United States Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 117. United States Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 118. United States Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 119. United States Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 120. Canada Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 121. Canada Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 122. Canada Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 123. Canada Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 124. Mexico Hyperhidrosis Treatment, by Type USD Million (2018-2023)
  • Table 125. Mexico Hyperhidrosis Treatment, by Application USD Million (2018-2023)
  • Table 126. Mexico Hyperhidrosis Treatment, by Disease Type USD Million (2018-2023)
  • Table 127. Mexico Hyperhidrosis Treatment, by Diagnosis USD Million (2018-2023)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Hyperhidrosis Treatment: by Type(USD Million)
  • Table 136. Hyperhidrosis Treatment Antiperspirants , by Region USD Million (2025-2030)
  • Table 137. Hyperhidrosis Treatment Iontophoresis , by Region USD Million (2025-2030)
  • Table 138. Hyperhidrosis Treatment Botulinum toxin injections , by Region USD Million (2025-2030)
  • Table 139. Hyperhidrosis Treatment Prescription cloth wipes , by Region USD Million (2025-2030)
  • Table 140. Hyperhidrosis Treatment Prescription medicine , by Region USD Million (2025-2030)
  • Table 141. Hyperhidrosis Treatment Surgery , by Region USD Million (2025-2030)
  • Table 142. Hyperhidrosis Treatment: by Application(USD Million)
  • Table 143. Hyperhidrosis Treatment Hospitals , by Region USD Million (2025-2030)
  • Table 144. Hyperhidrosis Treatment Dermatology Clinics , by Region USD Million (2025-2030)
  • Table 145. Hyperhidrosis Treatment Other , by Region USD Million (2025-2030)
  • Table 146. Hyperhidrosis Treatment: by Disease Type(USD Million)
  • Table 147. Hyperhidrosis Treatment Primary Focal Hyperhidrosis , by Region USD Million (2025-2030)
  • Table 148. Hyperhidrosis Treatment Secondary Generalized Hyperhidrosis , by Region USD Million (2025-2030)
  • Table 149. Hyperhidrosis Treatment: by Diagnosis(USD Million)
  • Table 150. Hyperhidrosis Treatment Physical Examination , by Region USD Million (2025-2030)
  • Table 151. Hyperhidrosis Treatment Sweat Test , by Region USD Million (2025-2030)
  • Table 152. Hyperhidrosis Treatment Others , by Region USD Million (2025-2030)
  • Table 153. South America Hyperhidrosis Treatment, by Country USD Million (2025-2030)
  • Table 154. South America Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 155. South America Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 156. South America Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 157. South America Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 158. Brazil Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 159. Brazil Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 160. Brazil Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 161. Brazil Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 162. Argentina Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 163. Argentina Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 164. Argentina Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 165. Argentina Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 166. Rest of South America Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 167. Rest of South America Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 168. Rest of South America Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 169. Rest of South America Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 170. Asia Pacific Hyperhidrosis Treatment, by Country USD Million (2025-2030)
  • Table 171. Asia Pacific Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 172. Asia Pacific Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 173. Asia Pacific Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 174. Asia Pacific Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 175. China Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 176. China Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 177. China Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 178. China Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 179. Japan Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 180. Japan Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 181. Japan Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 182. Japan Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 183. India Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 184. India Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 185. India Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 186. India Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 187. South Korea Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 188. South Korea Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 189. South Korea Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 190. South Korea Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 191. Taiwan Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 192. Taiwan Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 193. Taiwan Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 194. Taiwan Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 195. Australia Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 196. Australia Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 197. Australia Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 198. Australia Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 199. Rest of Asia-Pacific Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 200. Rest of Asia-Pacific Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 203. Europe Hyperhidrosis Treatment, by Country USD Million (2025-2030)
  • Table 204. Europe Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 205. Europe Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 206. Europe Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 207. Europe Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 208. Germany Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 209. Germany Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 210. Germany Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 211. Germany Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 212. France Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 213. France Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 214. France Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 215. France Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 216. Italy Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 217. Italy Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 218. Italy Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 219. Italy Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 220. United Kingdom Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 221. United Kingdom Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 222. United Kingdom Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 223. United Kingdom Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 224. Netherlands Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 225. Netherlands Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 226. Netherlands Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 227. Netherlands Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 228. Rest of Europe Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 229. Rest of Europe Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 230. Rest of Europe Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 231. Rest of Europe Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 232. MEA Hyperhidrosis Treatment, by Country USD Million (2025-2030)
  • Table 233. MEA Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 234. MEA Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 235. MEA Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 236. MEA Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 237. Middle East Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 238. Middle East Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 239. Middle East Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 240. Middle East Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 241. Africa Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 242. Africa Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 243. Africa Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 244. Africa Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 245. North America Hyperhidrosis Treatment, by Country USD Million (2025-2030)
  • Table 246. North America Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 247. North America Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 248. North America Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 249. North America Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 250. United States Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 251. United States Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 252. United States Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 253. United States Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 254. Canada Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 255. Canada Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 256. Canada Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 257. Canada Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 258. Mexico Hyperhidrosis Treatment, by Type USD Million (2025-2030)
  • Table 259. Mexico Hyperhidrosis Treatment, by Application USD Million (2025-2030)
  • Table 260. Mexico Hyperhidrosis Treatment, by Disease Type USD Million (2025-2030)
  • Table 261. Mexico Hyperhidrosis Treatment, by Diagnosis USD Million (2025-2030)
  • Table 262. Research Programs/Design for This Report
  • Table 263. Key Data Information from Secondary Sources
  • Table 264. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hyperhidrosis Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Hyperhidrosis Treatment: by Application USD Million (2018-2023)
  • Figure 6. Global Hyperhidrosis Treatment: by Disease Type USD Million (2018-2023)
  • Figure 7. Global Hyperhidrosis Treatment: by Diagnosis USD Million (2018-2023)
  • Figure 8. South America Hyperhidrosis Treatment Share (%), by Country
  • Figure 9. Asia Pacific Hyperhidrosis Treatment Share (%), by Country
  • Figure 10. Europe Hyperhidrosis Treatment Share (%), by Country
  • Figure 11. MEA Hyperhidrosis Treatment Share (%), by Country
  • Figure 12. North America Hyperhidrosis Treatment Share (%), by Country
  • Figure 13. Global Hyperhidrosis Treatment share by Players 2023 (%)
  • Figure 14. Global Hyperhidrosis Treatment share by Players (Top 3) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Allergan, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 17. Allergan, Inc. (United States) Revenue: by Geography 2023
  • Figure 18. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2023
  • Figure 20. Revance Therapeutics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Revance Therapeutics Inc. (United States) Revenue: by Geography 2023
  • Figure 22. Ulthera, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Ulthera, Inc. (United States) Revenue: by Geography 2023
  • Figure 24. TheraVida, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. TheraVida, Inc. (United States) Revenue: by Geography 2023
  • Figure 26. Dermira, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Dermira, Inc. (United States) Revenue: by Geography 2023
  • Figure 28. Sientra Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Sientra Inc. (United States) Revenue: by Geography 2023
  • Figure 30. Global Hyperhidrosis Treatment: by Type USD Million (2025-2030)
  • Figure 31. Global Hyperhidrosis Treatment: by Application USD Million (2025-2030)
  • Figure 32. Global Hyperhidrosis Treatment: by Disease Type USD Million (2025-2030)
  • Figure 33. Global Hyperhidrosis Treatment: by Diagnosis USD Million (2025-2030)
  • Figure 34. South America Hyperhidrosis Treatment Share (%), by Country
  • Figure 35. Asia Pacific Hyperhidrosis Treatment Share (%), by Country
  • Figure 36. Europe Hyperhidrosis Treatment Share (%), by Country
  • Figure 37. MEA Hyperhidrosis Treatment Share (%), by Country
  • Figure 38. North America Hyperhidrosis Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Allergan, Inc. (United States)
  • GlaxoSmithKline Plc (United Kingdom)
  • Revance Therapeutics Inc. (United States)
  • Ulthera, Inc. (United States)
  • TheraVida, Inc. (United States)
  • Dermira, Inc. (United States)
  • Sientra Inc. (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 210 Pages 88 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hyperhidrosis Treatment Market Quantitative research analysis
Global Hyperhidrosis Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Allergan, Inc. (United States), GlaxoSmithKline Plc (United Kingdom), Revance Therapeutics Inc. (United States), Ulthera, Inc. (United States), TheraVida, Inc. (United States), Dermira, Inc. (United States) and Sientra Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing Focus on Preventive Healthcare" is seen as one of major influencing trends for Hyperhidrosis Treatment Market during projected period 2023-2030.
The Hyperhidrosis Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Hyperhidrosis Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Allergy Diagnostics And Treatment Comprehensive Study by Application (Diagnostic Laboratories, Hospital-Based Laboratories, Academic Research Institutes, Other End Users), Tests Type (Specific IgE te...
$ 3750
Monoclonal Antibodies Drug Comprehensive Study by Application (Oncology, Autoimmune, Inflammatory Diseases, Respiratory Diseases, Ophthalmology, Others), Origin (Murine Antibodies, Human Antibodies, ...
$ 3650
Medical Skincare Comprehensive Study by Type (Cleansers, Toners, Scrubs & Masks, Serums, Moisturizers, Eye Creams, SPF, Others), Application (Acne, Anti-Aging, Brightening, Sensitive Skin, Dry Skin, ...
$ 3750
Weight Loss Therapeutics Comprehensive Study by Therapy (Intensive Behavioural Therapy, Self-Monitoring Therapy), End Users (Hospitals, Therapy Clinics, Pharmaceuticals Organization), Distribution Ch...
$ 3650
Genitourinary System Treatment Comprehensive Study by Type (OTC, Rx Drugs), Application (Hospital, Clinics, Ambulatory Surgical Centers), Drugs (Hormonal Therapy, Impotence Agents, Uterine Relaxants,...
$ 3750
Biliary Tumor Comprehensive Study by Type (Mecine, Surgery, Other), Application (Hospitals, Clinics, Other) Players and Region - Global Market Outlook to 2029
$ 3500